Propofol exerts anti-hepatocellular carcinoma by microvesicle-mediated transfer of miR-142-3p from macrophage to cancer cells

RPMI 1640 was obtained from GIBCO (Invitrogen, Carlsbad, CA, USA). Fetal bovine serum (FBS) was obtained from Hyclone (Logan, UT, USA). Lipofectamine 2000 transfection reagent was obtained from Invitrogen Life Technologies (Grand Island, NY, USA). Propofol was purchased from Sigma Aldrich (St Louis, MO, USA). A cholesterol-conjugated miR-142-3p inhibitor and a negative control (Nc) oligonucleotide for in vivo RNA delivery were purchased from RiboBio (Guangzhou, China). Antibodies against RAC1 and GAPDH were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). A detergent-compatible protein assay kit was purchased from Bio-Rad Laboratories (Hercules, CA, USA). An miRNeasy Mini kit, miScript Reverse Transcription kit, and miScript SYBR Green PCR kit were purchased from Qiagen (Hilden, Germany). Clodronate encapsulated in liposome nanoparticles (5 mg/ml) was purchased from Encapsula Nanosciences Inc.

A mouse HCC cell line, Hepa1-6, and a mouse macrophage cell line, Raw 264.7, were obtained from the Chinese Academy of Sciences (Shanghai, China). The cells were cultured in complete RPMI 1640 with 10% FBS and treated with propofol (dissolved in RPMI 1640) in complete medium. To obtain reliable results, the final concentration of RPMI 1640 in the culture medium was less than 0.1%.

All the experiments were approved by the Experimental Animal Ethics Committee of Zhejiang University and performed under the guidelines of the Institutional Animal Care and Use Committee. Male C57L/J 8-week-old mice were purchased from Shanghai Laboratory Animal Centre (Chinese Academy of Sciences). Hepa1-6 cells (5 × 10⁶ cells) were injected into the right flank of the C57L/J mice for 5 days. The mice were then randomly divided and assigned to the following treatments (n = 8 in each group): 20 mg/kg of propofol, 100 μg/kg of clodrolip, 20 μmg/kg of propofol + 100 μg/kg of clodrolip, 50 mg/kg of propofol, 50 mg/kg of propofol + 100 μg/kg of clodrolip, 20 μg of MVs, the miR-142-3p inhibitor, or 20 mg/kg of propofol + the miR-142-3p inhibitor. Propofol in 0.5 ml of soybean oil was administered by intraperitoneal (i.p.) injection once a day for 3 weeks. For macrophage depletion, 100 μl of clodronate liposomes were injected via the i.p. route into the tumor-bearing mice weekly. The Nc and the miR-142-3p inhibitor (10 nmol) in 0.1 ml of saline buffer were administered intratumorally every 2 days for 3 weeks. Tumor growth was assessed twice a week with a caliper measurement, and the volume (V) was calculated using the formula V = 1/2 × length × (width)².

Tumor-associated macrophages (TAMs) were isolated from the tumors according to previous report [24]. Briefly, small pieces of solid tumors tissue was digested with0.125% (wt/vol) Trypsin (Sigma) for 40 minutes at 37°C, followed by washing twice in incomplete RPMI 1640 medium. Cells were seeded in dishes of RPMI 1640 medium with 10% FBS and, after 12 h of incubation, non-adherent cells were vigorously washed off. The adherent cells were greater than 95% macrophages.

The MVs were isolated from the cell culture medium by differential centrifugation according to the method described in a previous report [21]. The cells and cell debris were removed by centrifugation at 300 × g for 10 min, 1200 × g for 10 min, and 10000 × g for 30 min. Supernatant was sequentially centrifuged at 11,0000 × g for 2 h (all steps were performed at 4°C). The MVs were collected from the pellet and resuspended in phosphate buffer saline (PBS) buffer. The total protein content in the MVs was measured, and the levels of MVs were determined by measuring the total protein content, which is presented as micrograms of total protein in the MVs.

The full-length coding sequence for mouse RAC1 was amplified by PCR from the mouse full-length cDNA based on GeneBank sequences. DNA encoding the RAC1 was subcloned from pCMV3.0b-myc-RAC1 into pAdTrack-CMV. All the sequences were confirmed by automated DNA sequencing. These shuttle plasmids were then recombined with the backbone vector pAdEasy-1 in BJ5183 bacteria. Viral particles were purified using the Virabind™ Adenovirus Purification Kit (Cell Biolabs, Inc., San Diego, CA, USA). Raw 264.7 cells were infected with adenovirus at an MOI of 100 at 37°C for 2 h. The cells were then cultured in fresh medium for 24 h or 48 h.

Hepa1-6 and Raw 264.7 cells were seeded in 6-well or 24-well plates and transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. For the knockdown of miR-142-3p, miR-142-3p inhibitor or a negative-control (Nc) was used at the concentration of 100 nM. The cells were treated with propofol after the transfection for 24 h.

Approximately 5 × 10⁶ cells were treated with or without (control) propofol for 24 h. Mature miRNAs were isolated and purified using Trizol reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's protocol. The levels of miR-142-3p, miR-199a, miR-122, and miR-29 were quantified with a TaqMan PCR kit. Real-time PCR was performed with LightCycler 480, using U6 small nuclear RNA as an internal normalized reference.

The expression of mRNA was measured using SYBR GREEN PCR Master Mix (Applied Biosystems). The specific primers were as follows: RAC1, 5'-TTGCCAAAATACCTTCTGAACT-3' (forward) and 5'-TGCTTTACGCATCTGAGAACTA-3' (reverse); GAPDH, 5'-TGAAGCAGGCA TCTGAGGG-3' (forward) and 5'-CGAAGGTGGAAGAGTGGGAG-3' (reverse). All data were analyzed using GAPDH gene expression as an internal standard.

The tumor invasion assay used modified Boyden chambers (8-μm pore size, BD Biosciences, USA), in which the various cellular components were grown without direct cell-to-cell contact. Briefly, the membrane was coated with Matrigel (BD) diluted 1/5 in serum-free DMEM media on ice. Hepa1-6 cells (1 × 10⁵ cells) were seeded in the upper well of the chamber, and the lower well was filled with TAMs. After co-culture for 24 h, the transwells were removed from the 24-well plates, and the non-invaded cells were scraped off the top of the Transwell filters with a cotton swab. The filter was fixed formaldehyde (4%) and stained with 0.1% crystal violet in 2% methanol. Invasiveness was determined by counting cells in five microscopic fields per well, and the extent of invasion was expressed as an average number of cells per microscopic field.

Statistical analysis was performed with SPSS 13.0 software. The statistical analyses used an analysis of variance (ANOVA) or the Student's t-test. Data were expressed as the mean ± standard deviation. P<0.05 was considered significant.

Our previous study showed that propofol induced apoptosis and impaired the invasiveness of HCC cell lines in vitro[14],[15]. To evaluate the effects of propofol on HCC in vivo, we examined tumor growth in tumor-bearing mice treated with propofol. The size of the tumors significantly decreased in a dose-dependent manner following the i.p. injection of 20 and 50 mg/kg of propofol (Figure 1A). The tumor-bearing mice were sacrificed on Day 26 after the injection of the Hepa1-6 cells. The mean tumor volume, which was 276.67 ± 25.17 mm³ in the control group, was dose-dependently reduced in the propofol treatment group (183.33 ± 20.83 mm³ in the 20 mg/kg group and 103.33 ± 15.28 mm³ in the 50 mg/kg group) (Figure 1B).

To determine whether the administration of propofol elicited the activation of macrophages within a HCC environment, we analyzed the expression of TNF-αand CD206 in the TAMs of the hepatoma-bearing mice injected with different amounts of propofol. The TAMs from the propofol-injected mice had higher expression of TNF-α but lower expression of CD206 (Figure 1C and D).

To explore the mechanism underling the involvement of TAMs in the antitumor activity of propofol, we measured the expression of a number of miRNAs, including miR-142-3p, miR-199a, miR-122, and miR-29, which may act as tumor suppressors in HCC [23]. Hepa1-6 cells cocultured with TAMs (1:1) from the propofol-treated HCC tissue exhibited a dose-dependent increase in cellular miR-142-3p levels relative to cells that were cocultured with TAMs from soybean oil-treated HCC tissue (Figure 2A). However, there was no change in the expression of miR-199a, miR-122, and miR-29 (Figure 2B). The expression of RAC1, a known target of miR-142-3p [25], was significantly down-regulated in the HCC cells following incubation with TAMs from the propofol-treated HCC tissue (Figure 2C and 2D), suggesting that the level of functional miR-142-3p levels increased in the HCC cells.

A previous study demonstrated that miR-142-3p prevents the differentiation of macrophages and inhibits their immunosuppressive function in tumors [24]. To determine whether propofol treatment stimulated miR-142-3p shuttling from macrophages to the HCC cells, we determined the expression of miR-142-3p in macrophages and MVs secreted from macrophages. As expected, the expression of miR-142-3p in the TAMs of the tumor-bearing mice injected with propofol was obviously increased compared with those of the soybean oil-injected mice (Figure 3A). Consistent with this observation, the level of miR-142-3p in the MVs from the propofol-treated TAMs was also higher than that in the soybean oil-treated mice (Figure 3B). The levels of miR-142-3p were significantly increased in the Hepa1-6 cells incubated with the MVs of the propofol-treated TAMs (Figure 3C). Furthermore, the migration of Hepa1-6 cells was significantly decreased (Figure 3D).

We further analyzed the effect of propofol on the expression of miR-142-3p in macrophages and MVs in vitro. Briefly, the Raw 264.7 cells were exposed to different concentrations of propofol for 24 h. The levels of miR-142-3p were dose-dependently elevated in both macrophages and MVs (Figure 3E and 3F). The incubation with the MVs from the propofol-treated Raw 264.7 cells significantly inhibited the migration of Hepa1-6 cells (Figure 3G). Overexpression of RAC1 in Hepa1-6 cells reversed the effect of these MVs on the migration of the HCC cells (Figure 3H). However, the expression of miR-142-3p was not up-regulated when the Hepa1-6 cells were directly treated with propofol (Figure 3I).

To further explore the role of MVs in anti-HCC, we collected MVs from the plasma of the tumor-bearing mice injected with or without propofol (20 mg/kg). Plasma miR-142-3p levels were increased in the tumor-bearing mice treated with the MVs of the propofol-injected mice (Figure 4A). Tumor growth was also significantly inhibited in these mice (Figure 4B and 4C). These results suggest that secreted miR-142-3p may be involved in the anti-HCC effect of propofol.

To further explore the role of miR-142-3p in MVs from macrophages, we treated Raw 264.7 cells with an miR-142-3p inhibitor. The results of real-time PCR showed that the miR-142-3p inhibitor profoundly reduced the levels of miR-142-3p in the Raw 264.7 cells and MVs (Figure 5A and 5B). The MVs from the propofol-treated cells (5 μg/ml) that were transfected with the miR-142-3p inhibitor significantly decreased miR-142-3p levels in Hepa1-6 cells and stimulated the migration of these cells (Figure 5C and 5D).

After an intratumoral injection of the miR-142-3p inhibitor, the size of the tumors in the tumor-bearing mice slightly increased. However, the inhibition of tumor growth by propofol (20 mg/kg) was restored by the miR-142-3p inhibitor (Figure 5E and 5F). These results indicate that miR-142-3p was involved in the anti-HCC activity of propofol.